Oncology

Latest News

Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC

September 8th 2025

Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.

Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2
Clinical Advances in EGFR-Mutated NSCLC: Insights From MARIPOSA and FLAURA2

September 7th 2025

Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC

September 7th 2025

Microscopic view of non small cell lung cancer cells. Image Credit: © Keopaserth - stock.adobe.com
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC

September 6th 2025

Lung cancer. Image Credit: © Dr Microbe - stock.adobe.com
Comparing Global Standards in Lung Cancer: NCCN, ESMO, and CHEST Guidelines

September 6th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations
Continuing Medical Education
View All
September 9th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 9th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Roche Sues Pfizer to Block Its Biosimilar Referencing Herceptin
November 23rd 2017

Roche Sues Pfizer to Block Its Biosimilar Referencing Herceptin

Jaime Rosenberg
Roche is suing Pfizer to block the company from selling a biosimilar referencing its breast-cancer drug Herceptin in the United States, claiming that the biosimilar infringes on 40 of its patents.
Chemotherapy, Radiation Therapy Recommended First for Certain Prostate Cancers, Lymphomas
November 22nd 2017

Chemotherapy, Radiation Therapy Recommended First for Certain Prostate Cancers, Lymphomas

Laura Joszt, MA
Chemotherapy and radiation therapy should be the first line of treatment for certain prostate cancers and lymphomas with a major genetic weakness, according to researchers at the University of Virginia School of Medicine.
Site Logo
November 21st 2017

Analysis Identifies Attributes That Likely Contribute to High-Value Oncology Care

Jaime Rosenberg
An analysis using mixed quantitative and qualitative methods, as well as site visits to 7 US oncology practices, identified 13 attributes within 5 themes that potentially contribute to high-quality care at a relatively low total cost.
Site Logo
November 18th 2017

Navigators Offer Touch Points on Patients' Cancer Journey

Mary Caffrey
The evolution of the navigator role has been an important development in cancer care, according to panelists who offered various perspectives on helping patients along the cancer journey.
Site Logo
November 18th 2017

NQF and CAPC Team Up to Set Quality Standards for Community-Based Serious Illness Care

Jaime Rosenberg
With the growing shift to community-based and patient-centered care, the National Quality Forum (NQF) and the Center to Advance Palliative Care (CAPC) have launched initiatives to ensure that patients with serious illness receive safe, effective, and high-quality care. At the same time, professionals in the healthcare industry are highlighting the importance of integrating this type of care into the oncology practice.
ASCO's TAPUR Study Expands to Enroll Patients Receiving Immunotherapy
November 17th 2017

ASCO's TAPUR Study Expands to Enroll Patients Receiving Immunotherapy

AJMC Staff
With an expansion that includes immunotherapy combination treatments, the American Society of Clinical Oncology (ASCO)’s Targeted Agent and Profiling Utilization Registry (TAPUR) Study has now grown to 500 participants and 16 therapies.
Site Logo
November 17th 2017

Oncologists Can Save Oncology If They Take Ownership of Costs, Kolodziej Says

Mary Caffrey
High chemotherapy costs are only one reason for the rising cost of cancer care. End-of-life care and hospitalizations are within an oncologist's control and must be better managed given new reimbursement structures.
Study Finds Oncology Care Is Cheaper in Community Settings Than Hospital-Based Practices
November 17th 2017

Study Finds Oncology Care Is Cheaper in Community Settings Than Hospital-Based Practices

Jaime Rosenberg
Authors of the study found that the mean total, chemotherapy, and physician costs were all lower in community settings compared with hospital-based settings for patients with breast, lung, and colorectal cancer. There were also fewer emergency department visits both 3 and 10 days following treatment.
FDA Action on MSK Tumor Profiling Assay Breaks Ground on Multiple Fronts
November 17th 2017

FDA Action on MSK Tumor Profiling Assay Breaks Ground on Multiple Fronts

Mary Caffrey
FDA on Thursday authorized a faster approval path for a next-generation sequencing assay developed at Memorial Sloan Kettering Cancer Center (MSK) that represents both a scientific and regulatory breakthrough at the agency.
Predicting Which Patients Will Benefit From Immunotherapy
November 16th 2017

Predicting Which Patients Will Benefit From Immunotherapy

AJMC Staff
A mathematical model may help providers better understand which patients will benefit from certain immunotherapy.
Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors
November 15th 2017

Hematological Toxicities and Febrile Neutropenia Resulting From CDK 4/6 Inhibitors

AJMC Staff
Cyclin-dependent kinase 4/6 inhibitors may have proven benefits for treating metastatic breast cancer, but the therapies are associated with hematological toxicities and febrile neutropenia.
Dr Amy Abernethy on Improving Patient Access to Oncology Clinical Trials
November 14th 2017

Dr Amy Abernethy on Improving Patient Access to Oncology Clinical Trials

As oncology moves toward more deep diagnostic testing and as standard of care continues to quickly evolve, technology advancements are necessary to continue to improve patient access to clinical trials, explained Amy Abernethy, MD, PhD, the chief medical officer, chief scientific officer, and senior vice president of oncology at Flatiron Health.
Do Oral Parity Laws Reduce OOP Spending for Patients?
November 14th 2017

Do Oral Parity Laws Reduce OOP Spending for Patients?

Surabhi Dangi-Garimella, PhD
According to a new analysis by Stacy Dusetzina, PhD, and colleagues, state oral parity laws—devised to equate out-of-pocket (OOP) spending for patients, irrespective of whether their treatment is an oral agent or an infusion—are not consistent with reducing patient OOP costs for oral anticancer agents.
Site Logo
November 14th 2017

The Influence of Provider Characteristics and Market Forces on Response to Financial Incentives

Brock O&rsquo Neil, MD Mark Tyson, MD Amy J. Graves, SM, MPH Daniel A. Barocas, MD, MPH Sam S. Chang, MD, MBA David F. Penson, MD, MPH Matthew J. Resnick, MD, MPH
We determine a specialist physician phenotype responsive to financial incentives that may be leveraged to identify physicians and markets well-suited for participation in alternative payment models.
NEHI Recommends Implementing Value-Based Contracts With High-Cost Oncology Treatments
November 12th 2017

NEHI Recommends Implementing Value-Based Contracts With High-Cost Oncology Treatments

Smita Jaggernauth, PharmD
A new white paper from the Network for Excellence in Health Innovation encourages the use of outcomes-based contracting for novel oncology drugs.
Podcast: This Week in Managed Care—Healthcare on Election Day 2017, and Other Health News
November 11th 2017

Podcast: This Week in Managed Care—Healthcare on Election Day 2017, and Other Health News

Every week, The American Journal of Managed Care® recaps the top managed care news of the week, and you can now listen to it on our podcast, Managed Care Cast.
This Week in Managed Care: November 10, 2017
November 10th 2017

This Week in Managed Care: November 10, 2017

This week, the top managed care stories included a vote in Maine to expand Medicaid and other election day 2017 results; CMS issued final rules for the DIabetes Prevention Program; and a report from the American Society of Clinical Oncology highlighted the link between alcohol consumption and cancer.
Mutation May Be Associated With Resistance to NSCLC Immunotherapy
November 8th 2017

Mutation May Be Associated With Resistance to NSCLC Immunotherapy

Smita Jaggernauth, PharmD
A specific mutation has been linked with acquired resistance in immunotherapy drugs used to treat non–small lung cancer (NSCLC).
The American Journal of Managed Care® Announces Dr Michael Kolodziej as the Keynote Speaker for the Patient-Centered Oncology Care® Meeting
November 8th 2017

The American Journal of Managed Care® Announces Dr Michael Kolodziej as the Keynote Speaker for the Patient-Centered Oncology Care® Meeting

Leading healthcare innovation officer to share information about digital health, managed services, and provider sectors in the healthcare arena.
Tesh Khullar: Community Oncologists Need to Understand Impact of Biosimilars on Their Business
November 8th 2017

Tesh Khullar: Community Oncologists Need to Understand Impact of Biosimilars on Their Business

Biosimilars for core therapeutics in cancer are starting to come out, and community oncologists need to understand what that means for their business, as well as what proposed policy changes could mean for reimbursement, explained Tesh Khullar,
Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC
November 8th 2017

Roche Gets Drug Approvals for First Treatment for a Rare Blood Disorder and NSCLC

AJMC Staff
Roche had 2 drugs approved by the FDA—one that is the first approved treatment for a rare blood disease and the other is approved as a first-line treatment for anaplastic lymphoma kinase-positive metastatic non–small cell lung cancer.
ASCO: Alcohol Linked to Several Types of Cancer
November 8th 2017

ASCO: Alcohol Linked to Several Types of Cancer

Jaime Rosenberg
According to evidence gathered by the American Society of Clinical Oncology (ASCO), alcohol consumption is linked with an increased risk of cancer and can negatively impact cancer treatment.
Study to Explore Link Between Diabetes, Pancreatic Cancer
November 7th 2017

Study to Explore Link Between Diabetes, Pancreatic Cancer

Mary Caffrey
Rising rates of diabetes and obesity have been cited in the fact that pancreatic cancer is expected to be the second-leading cause of cancer death by 2020.
Incidence Rates of Early-Stage Breast and Colorectal Cancer Increased Following Enactment of ACA
November 7th 2017

Incidence Rates of Early-Stage Breast and Colorectal Cancer Increased Following Enactment of ACA

Jaime Rosenberg
With the ACA putting emphasis on preventive care, there has been an immediate increase in breast and coloreactal cancer screenings. A recent study found that incidence rates of early-stage breast and colorectal cancer increased in 2014, but did not vary for late-stage breast and colorectal cancer.
3D Mammograms and Breath Test Represent Advances in Breast Cancer Detection Technology
November 5th 2017

3D Mammograms and Breath Test Represent Advances in Breast Cancer Detection Technology

Alison Rodriguez
Recent advancements in technology, specifically in detection methods, have demonstrated significant improvement in how early patients are diagnosed with breast cancer and treated.
Managing Neutropenia Toxicity With CDK 4/6 Inhibitors Used to Treat Metastatic Breast Cancer
November 4th 2017

Managing Neutropenia Toxicity With CDK 4/6 Inhibitors Used to Treat Metastatic Breast Cancer

Laura Joszt, MA
In a pair of interviews, experts discuss neutropenia resulting from treatment of metastatic breast cancer with CDK4/6 inhibitors.
This Week in Managed Care: November 3, 2017
November 3rd 2017

This Week in Managed Care: November 3, 2017

AJMC Staff
This week, the top managed care news included the first day of open enrollment; data from CMS that indicate the progress accountable care organizations are making; and findings that most people with obesity aren't get screened for it or getting care.
Fiber Intake Associated With Lower Mortality in Patients with Colorectal Cancer
November 3rd 2017

Fiber Intake Associated With Lower Mortality in Patients with Colorectal Cancer

Jaime Rosenberg
Increased fiber, especially from cereal, intake after the diagnosis of non-metastatic colorectal cancer (CRC) is associated with lower CRC-specific and overall mortality.
FDA Approves New Treatment for Adults With Mantle Cell Lymphoma
November 1st 2017

FDA Approves New Treatment for Adults With Mantle Cell Lymphoma

Jaime Rosenberg
Mantle cell lymphoma is an aggressive type of non-Hodgkin lymphoma. Acalabrutinib (Calquence) is a kinase inhibitor that works by blocking an enzyme the cancer needs to multiply and spread.
FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer
November 1st 2017

FDA Grants Priority Review for Lilly's Verzenio for Metastatic Breast Cancer

Alison Rodriguez
The FDA has granted Priority Review designation for Eli Lilly and Company’s New Drug Application (NDA) for Verzenio (abemaciclib), a cyclindependent kinase 4 and 6 inhibitor for metastatic breast cancer. The decision was based on the MONARCH 3 study, which examined abemaciclib as an initial endocrine-based therapy.
<1
...
656667686970717273
...
188>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo